Ftse Mib
33.230,32
-0,26%
DAX
18.067,91
-0,31%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
64.914,57
-0,34%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Allakos Inc (ALLK) Allakos Inc (ALLK) Notizie

ALLK

Allakos (ALLK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALLK
DataOraFonteTitoloSimboloCompagnia
10/06/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
07/06/202421:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
28/05/202413:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
28/05/202413:02GlobeNewswire Inc.Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaNASDAQ:ALLKAllakos Inc
09/05/202423:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLKAllakos Inc
09/05/202422:02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:ALLKAllakos Inc
14/03/202421:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
26/02/202413:02GlobeNewswire Inc.Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024NASDAQ:ALLKAllakos Inc
17/02/202401:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
14/02/202422:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
12/02/202413:02GlobeNewswire Inc.Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
02/02/202418:31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALLKAllakos Inc
26/01/202422:20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALLKAllakos Inc
16/01/202413:02GlobeNewswire Inc.Allakos Announces a Restructuring to Focus on Development of AK006NASDAQ:ALLKAllakos Inc
16/01/202413:00GlobeNewswire Inc.Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsNASDAQ:ALLKAllakos Inc
05/01/202422:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALLKAllakos Inc
27/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLKAllakos Inc
13/11/202323:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLKAllakos Inc
13/11/202322:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
30/08/202322:05GlobeNewswire Inc.Allakos Appoints Neil Graham to its Board of DirectorsNASDAQ:ALLKAllakos Inc
09/08/202322:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
02/08/202322:05GlobeNewswire Inc.Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of DirectorsNASDAQ:ALLKAllakos Inc
12/06/202313:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALLKAllakos Inc
12/06/202313:02GlobeNewswire Inc.Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
05/06/202322:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALLKAllakos Inc
05/06/202313:02GlobeNewswire Inc.Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023NASDAQ:ALLKAllakos Inc
02/06/202322:51Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ALLKAllakos Inc
09/05/202322:14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALLKAllakos Inc
09/05/202322:02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
20/04/202322:25Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ALLKAllakos Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALLK

La tua Cronologia

BOV
BIDU34R
Baidu
BOV
UGPAU237
UGPAU237 Ex:23,35
USOTC
SUNFF
Sun Life Financial (PK)
USOTC
SMAS
Somatic Systems (CE)
BIT
F37933
Vontobel Financial Produ...
NASDAQ
OXACW
Oxbridge Acquisition
BIT
F37370
Vontobel Financial Produ...
LSE
BV85
Barclays 31
COIN
BNDDUSD
DokiDoki.Chainbinders
LSE
82KW
Caixa Pen Prf
AMEX
OGSP
Obra High Grade Structur...
TSX
CDIV
Manulife Smart Dividend ...
COIN
DIOETH
CRTO
ORDIUSD
Ordinals
LSE
15DZ
Euro.bk. 23
TG
SADE
Amundi Luxembourg
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network